Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China.

Tracheal cancer clinicopathological features surgery survival

Journal

Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875

Informations de publication

Date de publication:
May 2022
Historique:
received: 12 10 2021
accepted: 18 05 2022
entrez: 13 6 2022
pubmed: 14 6 2022
medline: 14 6 2022
Statut: ppublish

Résumé

Tracheal cancer is a rare malignancy of which previous reports are mostly case reports or small series. Herein, we sought to evaluate the clinical characteristics, surgical treatments, and prognosis of surgically treated primary tracheal cancer patients. Patients with primary tracheal cancer who had received surgery in our center between January 2000 and December 2020 were enrolled. Clinical and surgical features were collected by retrospective review of medical records and follow-up was done by telephone interview. The statistical tests were two-sided. A total of 128 patients were included in the study, 49.2% of whom were male, and the average age was 49.4±13.6 years. The most common histological subtype was adenoid cystic carcinoma (ACC; 78/128, 60.9%) followed by squamous cell carcinoma (SCC; 24/128, 18.8%). The percentage of tumors located in the cervical trachea, thoracic trachea, and carina were 50%, 41.4%, and 8.6%, respectively. Among those analyzed, 32.0% of the primary tumors had invaded adjacent organs (E2 disease) and 7.8% of patients had lymph node involvement. Tracheal resection plus reconstruction (with or without thyroidectomy) was the predominant surgical procedure, followed by carinal resection with neocarina. Radical resection (R0) was performed on 61.7% of patients and 63 (49.2%) patients received adjuvant therapy. Compared to ACC, SCC patients had significantly higher risk of tumor of the carina, nodal metastasis, and complications. The 5-year overall survival (OS) for the entire cohort was 84.5% and factors associated with poor prognosis included carinal tumor [hazard ratio (HR) =10.206; P<0.001], E2 disease (HR =8.870; P=0.001), lymph node metastasis (HR =15.197; P<0.001), and postoperative complications (HR =12.497; P=0.001). The two major subtypes of tracheal cancer are ACC and SCC. Tumor location, extension, lymph node metastasis and complication are survival related factors for surgically treated patients.

Sections du résumé

Background UNASSIGNED
Tracheal cancer is a rare malignancy of which previous reports are mostly case reports or small series. Herein, we sought to evaluate the clinical characteristics, surgical treatments, and prognosis of surgically treated primary tracheal cancer patients.
Methods UNASSIGNED
Patients with primary tracheal cancer who had received surgery in our center between January 2000 and December 2020 were enrolled. Clinical and surgical features were collected by retrospective review of medical records and follow-up was done by telephone interview. The statistical tests were two-sided.
Results UNASSIGNED
A total of 128 patients were included in the study, 49.2% of whom were male, and the average age was 49.4±13.6 years. The most common histological subtype was adenoid cystic carcinoma (ACC; 78/128, 60.9%) followed by squamous cell carcinoma (SCC; 24/128, 18.8%). The percentage of tumors located in the cervical trachea, thoracic trachea, and carina were 50%, 41.4%, and 8.6%, respectively. Among those analyzed, 32.0% of the primary tumors had invaded adjacent organs (E2 disease) and 7.8% of patients had lymph node involvement. Tracheal resection plus reconstruction (with or without thyroidectomy) was the predominant surgical procedure, followed by carinal resection with neocarina. Radical resection (R0) was performed on 61.7% of patients and 63 (49.2%) patients received adjuvant therapy. Compared to ACC, SCC patients had significantly higher risk of tumor of the carina, nodal metastasis, and complications. The 5-year overall survival (OS) for the entire cohort was 84.5% and factors associated with poor prognosis included carinal tumor [hazard ratio (HR) =10.206; P<0.001], E2 disease (HR =8.870; P=0.001), lymph node metastasis (HR =15.197; P<0.001), and postoperative complications (HR =12.497; P=0.001).
Conclusions UNASSIGNED
The two major subtypes of tracheal cancer are ACC and SCC. Tumor location, extension, lymph node metastasis and complication are survival related factors for surgically treated patients.

Identifiants

pubmed: 35693280
doi: 10.21037/tlcr-22-258
pii: tlcr-11-05-735
pmc: PMC9186175
doi:

Types de publication

Journal Article

Langues

eng

Pagination

735-743

Informations de copyright

2022 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-258/coif). MVI serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. The other authors have no conflicts of interest to declare.

Références

Laryngoscope. 2020 Feb;130(2):405-412
pubmed: 30977524
Eur J Cardiothorac Surg. 2017 Aug 1;52(2):392-394
pubmed: 28633347
Ann Thorac Surg. 2019 Sep;108(3):873-882
pubmed: 31026435
Ann Thorac Surg. 2021 Mar;111(3):1093-1094
pubmed: 32710844
Lancet Oncol. 2006 Jan;7(1):83-91
pubmed: 16389188
Am J Otolaryngol. 2017 Nov - Dec;38(6):673-677
pubmed: 28927948
Ann Thorac Surg. 2021 Mar;111(3):1094
pubmed: 33189671
Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1888-1895
pubmed: 32418755
Lung Cancer. 2019 Jun;132:87-93
pubmed: 31097099
Am J Clin Oncol. 2011 Feb;34(1):32-7
pubmed: 20087156
Otolaryngol Head Neck Surg. 2004 Nov;131(5):639-42
pubmed: 15523440
J Surg Oncol. 2017 Jun;115(8):1004-1010
pubmed: 28407313
Ann Surg Oncol. 2007 Feb;14(2):968-76
pubmed: 17139460
Ann Thorac Surg. 2020 Sep;110(3):1012-1022
pubmed: 32335015
Eur J Cardiothorac Surg. 2003 Jan;23(1):1-5
pubmed: 12493495

Auteurs

Jiagen Li (J)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Fengwei Tan (F)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Yalong Wang (Y)

Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Qi Xue (Q)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Yushun Gao (Y)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Juwei Mu (J)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Yousheng Mao (Y)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Jun Zhao (J)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Dali Wang (D)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Xiaoli Feng (X)

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Susheng Shi (S)

Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Kenichi Suda (K)

Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Giuseppe Cardillo (G)

Unit of Thoracic Surgery, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy.

Luca Bertolaccini (L)

Department of Thoracic Surgery, IEO European Institute of Oncology IRCCS, Milan, Italy.

Maurizio V Infante (MV)

Department of Thoracic Surgery, University and Hospital Trust, Verona, Italy.

Paul E Van Schil (PE)

Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium.

Shugeng Gao (S)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Jie He (J)

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Classifications MeSH